Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04146935 · ClinicalTrials.gov registry record · Phase 4

Examining the Effect of Burosumab on Muscle Function

A Phase 4 study of X-linked Hypophosphatemia, sponsored by Yale University.

Completed
Registry status
Phase 4
Development phase
10
Enrollment target
1
Study location

NCT04146935 is a Phase 4 study of X-linked Hypophosphatemia that has completed, run by Yale University. The registered enrollment target is 10 participants, below the 172-participant average among 5 other X-linked Hypophosphatemia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04146935, a Phase 4 study of X-linked Hypophosphatemia, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 4
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Patients with X-linked hypophosphatemia (XLH) often report symptoms of fatigue and weakness particularly after exertion, in addition to their skeletal complaints. In previous trials using KRN23 (same drug as burosumab/Crysvita®), patients report these symptoms improve. The investigators wish to test this hypothesis directly by measuring muscle energy when patients begin treatment with Crysvita® for the first time.

Conditions Studied

X-linked Hypophosphatemia

Interventions

  • DRUG Burosumab Injection [Crysvita]

Study Locations (1)

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2019-11-13
Est. Completion 2022-08-25
Phase Phase 4

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04146935

The ClinicalTrials.gov registry entry for NCT04146935 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 172-participant average among 5 other X-linked Hypophosphatemia trials with a reported enrollment target (94% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with X-linked Hypophosphatemia appearing as the primary indexed condition, and to 1 intervention - of which Burosumab Injection [Crysvita] is the first listed.

NCT04146935 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT04146935 about?

NCT04146935 is a clinical study titled "Examining the Effect of Burosumab on Muscle Function". Patients with X-linked hypophosphatemia (XLH) often report symptoms of fatigue and weakness particularly after exertion, in addition to their skeletal complaints. In previous trials using KRN23 (same drug as burosumab/Crysvita®), patients report these symptoms improve. The investigators wish to test...

What is the current status of trial NCT04146935?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2019-11-13. Estimated completion is 2022-08-25.

What conditions does trial NCT04146935 study?

This clinical trial studies the following conditions: X-linked Hypophosphatemia.

What interventions are being tested in trial NCT04146935?

The interventions under investigation include: Burosumab Injection [Crysvita] (DRUG).

Who is sponsoring clinical trial NCT04146935?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04146935 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for X-linked Hypophosphatemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

X-linked Hypophosphatemia

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.